What Has Been the Growth of the AL Amyloidosis Market So Far?
The al amyloidosis market has seen considerable growth due to a variety of factors.
• The market size of AL amyloidosis has seen a swift expansion in the past few years. It is poised to rise from a valuation of $3.11 billion in 2024 to $3.52 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.2%.
Factors such as growing enlightenment of al amyloidosis among healthcare practitioners, an increase in al amyloidosis cases, a surge in the elderly population, the emergence of more diagnostic centers, and advancements in cardiac imaging are believed to have contributed to the growth in the historical period.
What Are the Future Growth Projections for the AL Amyloidosis Market?
The al amyloidosis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for AL amyloidosis is anticipated to witness a significant expansion in the coming years. The market is projected to increase to $5.74 billion by 2029 with a compound annual growth rate (CAGR) of 13.0%.
The growth in this forecast period may be credited to a surge in the number of blood cell DNA mutations, an expansive healthcare infrastructure, increasing cases of multiple myeloma, the introduction of new combined treatments, and a rise in the utilization of high-dose chemotherapy. Key trend predictions for the forecast period encompass advances in diagnostic methods, enhanced technology in medication delivery, progress in blood screenings, the emergence of targeted therapies, and the incorporation of artificial intelligence (AI) in diagnostic procedures.
What Are The Core Factors Supporting Growth In AL Amyloidosis Market?
The growth of the AL amyloidosis market is forecasted to accelerate due to the increasing occurrence of plasma cell disorders. These disorders are situations where disproportionate or out of the ordinary antibodies are produced by anomalous plasma cells, which can inflict organ damage. The upsurge in plasma cell illnesses can be traced back to factors such as a growing older demographic, longer life spans, and development in diagnostic technology. AL amyloidosis originates from plasma cell disorders, particularly the excessive production of aberrant proteins known as light chain proteins. This can result in a buildup of amyloid clumps in organs and tissues, escalating the impacts of plasma cell disorders. For instance, reports from The American Cancer Society (ACS), a US-based nonprofit organisation, projected that 35,780 new cases of multiple myeloma (19,520 in men and 16,260 in women), and approximately 12,540 deaths (7,020 in men and 5,520 in women) would be diagnosed in August 2024. Hence, the upward trend in plasma cell disorders is fueling the expansion of the AL amyloidosis market.
What Are The Major Segments Within The AL Amyloidosis Market?
The AL amyloidosis market covered in this report is segmented –
1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy
2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs
3) By Route Of Administration: Intravenous, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy
2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)
3) By Surgery: Organ Transplantation, Debulking Surgery
4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors
Pre-Book The AL Amyloidosis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The AL Amyloidosis Market?
Leading businesses in the AL amyloidosis industry are concentrating their efforts on developing groundbreaking therapies such as the newest B-cell maturation antigen (BCMA)-oriented CAR T-cell therapy. The goal is to enhance therapeutic effectiveness and patient wellbeing. This cutting-edge BCMA-based CAR T-cell therapy involves reprogramming a patient's T cells to identify and destroy BCMA on cancer cell surfaces, particularly multiple myeloma. To illustrate, in September 2023, Immix Biopharma Inc., a biopharmaceutical corporation based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) to market NXC-201, a remedy for Amyloid Light Chain (AL) Amyloidosis, a serious blood disorder. NXC-201 is a novel CAR-T cell therapy currently being studied in clinical trials as a potential treatment for AL amyloidosis. According to trial results, it demonstrates considerable potential, with a 100% hematologic response rate and organ improvements in patients previously unresponsive to other therapies.
Who Are the Key Players in the AL Amyloidosis Market?
Major companies operating in the AL amyloidosis market are include:
• Johnson & Johnson
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.
• Genmab A/S
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Prothena Corporation plc
• BridgeBio Pharma Inc.
• Sorrento Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Ultromics Ltd
• Neurimmune AG
• Immix Biopharma Inc.
• Oncopeptides AB
• Attralus Inc.
What Is The Most Dominant Region In The AL Amyloidosis Market?
North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
